{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:39:38Z","timestamp":1792510778233,"version":"4.5.0"},"reference-count":179,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10787-020-00757-9","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T19:02:31Z","timestamp":1600455751000},"page":"1457-1476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Current and novel therapeutic targets in the treatment of rheumatoid arthritis"],"prefix":"10.1007","volume":"28","author":[{"given":"Genu","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. L.","family":"Shyni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1341-5470","authenticated-orcid":false,"given":"K. G.","family":"Raghu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"key":"757_CR1","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/ni1496","volume":"8","author":"EV Acosta-Rodriguez","year":"2007","unstructured":"Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8:942\u2013949. https:\/\/doi.org\/10.1038\/ni1496","journal-title":"Nat Immunol"},{"key":"757_CR2","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1038\/sj.gt.3302104","volume":"10","author":"AO Afuwape","year":"2003","unstructured":"Afuwape AO, Feldmann M, Paleolog EM (2003) Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther 10:1950\u20131960. https:\/\/doi.org\/10.1038\/sj.gt.3302104","journal-title":"Gene Ther"},{"key":"757_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/ar2982","volume":"12","author":"S Ahmed","year":"2010","unstructured":"Ahmed S (2010) Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise. Arthritis Res Ther 12:208. https:\/\/doi.org\/10.1186\/ar2982","journal-title":"Arthritis Res Ther"},{"key":"757_CR4","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/art.22023","volume":"54","author":"S Ahmed","year":"2006","unstructured":"Ahmed S, Pakozdi A, Koch AE (2006) Regulation of interleukin-1beta-induced chemokine production and matrix metalloproteinase 2 activation by epigallocatechin-3-gallate in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 54:2393\u20132401. https:\/\/doi.org\/10.1002\/art.22023","journal-title":"Arthritis Rheum"},{"key":"757_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejr.2015.01.001","volume":"38","author":"HM Al-Saadany","year":"2016","unstructured":"Al-Saadany HM, Hussein MS, Gaber RA, Zaytoun HA (2016) Th-17 cells and serum IL-17 in rheumatoid arthritis patients: correlation with disease activity and severity. Egypt Rheumatol 38:1\u20137. https:\/\/doi.org\/10.1016\/j.ejr.2015.01.001","journal-title":"Egypt Rheumatol"},{"key":"757_CR6","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1136\/annrheumdis-2011-201024","volume":"71","author":"S Alzabin","year":"2012","unstructured":"Alzabin S, Abraham SM, Taher TE et al (2012) Incomplete response of inflammatory arthritis to TNF\u03b1 blockade is associated with the Th17 pathway. Ann Rheum Dis 71:1741\u20131748. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201024","journal-title":"Ann Rheum Dis"},{"key":"757_CR7","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.4110\/in.2018.18.e8","volume":"18","author":"DS Amarasekara","year":"2018","unstructured":"Amarasekara DS, Yun H, Kim S et al (2018) Regulation of osteoclast differentiation by cytokine networks. Immune Netw 18:e8. https:\/\/doi.org\/10.4110\/in.2018.18.e8","journal-title":"Immune Netw"},{"key":"757_CR8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M et al (2017) JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs 77:521\u2013546. https:\/\/doi.org\/10.1007\/s40265-017-0701-9","journal-title":"Drugs"},{"key":"757_CR9","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman K, Subesinghe S, Norton S et al (2019) A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatol (Oxford) 58:1755\u20131766. https:\/\/doi.org\/10.1093\/rheumatology\/kez087","journal-title":"Rheumatol (Oxford)"},{"key":"757_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1086\/422827","volume":"75","author":"AB Begovich","year":"2004","unstructured":"Begovich AB, Carlton VEH, Honigberg LA et al (2004) A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 75:330\u2013337. https:\/\/doi.org\/10.1086\/422827","journal-title":"Am J Hum Genet"},{"key":"757_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.molmed.2016.01.001","volume":"22","author":"A Beringer","year":"2016","unstructured":"Beringer A, Noack M, Miossec P (2016) IL-17 in chronic inflammation: from discovery to targeting. Trends Mol Med 22:230\u2013241. https:\/\/doi.org\/10.1016\/j.molmed.2016.01.001","journal-title":"Trends Mol Med"},{"key":"757_CR12","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","volume":"74","author":"DL Boyle","year":"2015","unstructured":"Boyle DL, Soma K, Hodge J et al (2015) The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis 74:1311\u20131316. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206028","journal-title":"Ann Rheum Dis"},{"key":"757_CR13","first-page":"945","volume":"27","author":"E Brouwer","year":"2009","unstructured":"Brouwer E, Gouw ASH, Posthumus MD et al (2009) Hypoxia inducible factor-1-alpha (HIF-1alpha) is related to both angiogenesis and inflammation in rheumatoid arthritis. Clin Exp Rheumatol 27:945\u2013951","journal-title":"Clin Exp Rheumatol"},{"key":"757_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/rheumatology\/kev258","volume":"55","author":"GR Burmester","year":"2016","unstructured":"Burmester GR, Durez P, Shestakova G et al (2016) Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis. Rheumatology 55:49\u201355. https:\/\/doi.org\/10.1093\/rheumatology\/kev258","journal-title":"Rheumatology"},{"key":"757_CR15","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F et al (2018) Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 391:2503\u20132512. https:\/\/doi.org\/10.1016\/S0140-6736(18)31115-2","journal-title":"Lancet"},{"key":"757_CR16","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1006\/cyto.2000.0681","volume":"12","author":"M Chabaud","year":"2000","unstructured":"Chabaud M, Garnero P, Dayer JM et al (2000) Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 12:1092\u20131099. https:\/\/doi.org\/10.1006\/cyto.2000.0681","journal-title":"Cytokine"},{"key":"757_CR17","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/ptr.4639","volume":"26","author":"B Chandran","year":"2012","unstructured":"Chandran B, Goel A (2012) A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res 26:1719\u20131725. https:\/\/doi.org\/10.1002\/ptr.4639","journal-title":"Phytother Res"},{"key":"757_CR18","doi-asserted-by":"publisher","first-page":"33714","DOI":"10.1074\/jbc.M704041200","volume":"282","author":"M Charbonneau","year":"2007","unstructured":"Charbonneau M, Harper K, Grondin F et al (2007) Hypoxia-inducible factor mediates hypoxic and tumor necrosis factor alpha-induced increases in tumor necrosis factor-alpha converting enzyme\/ADAM17 expression by synovial cells. J Biol Chem 282:33714\u201333724. https:\/\/doi.org\/10.1074\/jbc.M704041200","journal-title":"J Biol Chem"},{"key":"757_CR19","doi-asserted-by":"publisher","first-page":"R126","DOI":"10.1186\/ar3431","volume":"13","author":"D-Y Chen","year":"2011","unstructured":"Chen D-Y, Chen Y-M, Chen H-H et al (2011) Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-\u03b1 therapy. Arthritis Res Ther 13:R126. https:\/\/doi.org\/10.1186\/ar3431","journal-title":"Arthritis Res Ther"},{"key":"757_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s13075-015-0775-2","volume":"17","author":"C Choulaki","year":"2015","unstructured":"Choulaki C, Papadaki G, Repa A et al (2015) Enhanced activity of NLRP3 inflammasome in peripheral blood cells of patients with active rheumatoid arthritis. Arthritis Res Ther 17:257. https:\/\/doi.org\/10.1186\/s13075-015-0775-2","journal-title":"Arthritis Res Ther"},{"key":"757_CR21","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","volume":"57","author":"JD Clark","year":"2014","unstructured":"Clark JD, Flanagan ME, Telliez J-B (2014) Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases: miniperspective. J Med Chem 57:5023\u20135038. https:\/\/doi.org\/10.1021\/jm401490p","journal-title":"J Med Chem"},{"key":"757_CR22","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1002\/art.38779","volume":"66","author":"S Cohen","year":"2014","unstructured":"Cohen S, Radominski SC, Gomez-Reino JJ et al (2014a) Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis: all-cause mortality and infection rates in studies of tofacitinib. Arthritis Rheumatol 66:2924\u20132937. https:\/\/doi.org\/10.1002\/art.38779","journal-title":"Arthritis Rheumatol"},{"key":"757_CR23","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1002\/art.38779","volume":"66","author":"S Cohen","year":"2014","unstructured":"Cohen S, Radominski SC, Gomez-Reino JJ et al (2014b) Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol 66:2924\u20132937. https:\/\/doi.org\/10.1002\/art.38779","journal-title":"Arthritis Rheumatol"},{"key":"757_CR24","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X et al (2017) Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 76:1253\u20131262. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210457","journal-title":"Ann Rheum Dis"},{"key":"757_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0092-8674(03)00154-5","volume":"112","author":"T Cramer","year":"2003","unstructured":"Cramer T, Yamanishi Y, Clausen BE et al (2003) HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112:645\u2013657","journal-title":"Cell"},{"key":"757_CR26","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/febs.13578","volume":"283","author":"L D\u2019Ignazio","year":"2016","unstructured":"D\u2019Ignazio L, Bandarra D, Rocha S (2016) NF-\u03baB and HIF crosstalk in immune responses. FEBS J 283:413\u2013424. https:\/\/doi.org\/10.1111\/febs.13578","journal-title":"FEBS J"},{"key":"757_CR27","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/art.24503","volume":"60","author":"NA Daha","year":"2009","unstructured":"Daha NA, Kurreeman FAS, Marques RB et al (2009) Confirmation of STAT4, IL2\/IL21, and CTLA4 polymorphisms in rheumatoid arthritis. Arthritis Rheum 60:1255\u20131260. https:\/\/doi.org\/10.1002\/art.24503","journal-title":"Arthritis Rheum"},{"key":"757_CR28","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.2147\/DDDT.S175763","volume":"12","author":"Q Dai","year":"2018","unstructured":"Dai Q, Zhou D, Xu L, Song X (2018) Curcumin alleviates rheumatoid arthritis-induced inflammation and synovial hyperplasia by targeting mTOR pathway in rats. Drug Des Devel Ther 12:4095\u20134105. https:\/\/doi.org\/10.2147\/DDDT.S175763","journal-title":"Drug Des Devel Ther"},{"key":"757_CR29","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.4049\/jimmunol.1301970","volume":"192","author":"SG de Aquino","year":"2014","unstructured":"de Aquino SG, Abdollahi-Roodsaz S, Koenders MI et al (2014) Periodontal pathogens directly promote autoimmune experimental arthritis by inducing a TLR2- and IL-1-driven Th17 response. J Immunol 192:4103\u20134111. https:\/\/doi.org\/10.4049\/jimmunol.1301970","journal-title":"J Immunol"},{"key":"757_CR30","doi-asserted-by":"publisher","first-page":"e0194883","DOI":"10.1371\/journal.pone.0194883","volume":"13","author":"T Dhaouadi","year":"2018","unstructured":"Dhaouadi T, Chahbi M, Haouami Y et al (2018) IL-17A, IL-17RC polymorphisms and IL17 plasma levels in Tunisian patients with rheumatoid arthritis. PLoS One 13:e0194883. https:\/\/doi.org\/10.1371\/journal.pone.0194883","journal-title":"PLoS One"},{"key":"757_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4103\/1110-161X.168164","volume":"42","author":"AE Elhewala","year":"2015","unstructured":"Elhewala AE, Soliman S, Labib A et al (2015) Interleukin-17 level in rheumatoid arthritis patients and its relation to disease activity: a clinical and ultrasound study. Egypt Rheumatol Rehabil 42:183. https:\/\/doi.org\/10.4103\/1110-161X.168164","journal-title":"Egypt Rheumatol Rehabil"},{"key":"757_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10456-015-9477-2","volume":"18","author":"HA Elshabrawy","year":"2015","unstructured":"Elshabrawy HA, Chen Z, Volin MV et al (2015) The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis 18:433\u2013448. https:\/\/doi.org\/10.1007\/s10456-015-9477-2","journal-title":"Angiogenesis"},{"key":"757_CR33","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1056\/NEJMra0910283","volume":"364","author":"HK Eltzschig","year":"2011","unstructured":"Eltzschig HK, Carmeliet P (2011) Hypoxia and inflammation. N Engl J Med 364:656\u2013665. https:\/\/doi.org\/10.1056\/NEJMra0910283","journal-title":"N Engl J Med"},{"key":"757_CR34","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1073\/pnas.94.9.4273","volume":"94","author":"M Ema","year":"1997","unstructured":"Ema M, Taya S, Yokotani N et al (1997) A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci U S A 94:4273\u20134278. https:\/\/doi.org\/10.1073\/pnas.94.9.4273","journal-title":"Proc Natl Acad Sci U S A"},{"key":"757_CR35","doi-asserted-by":"publisher","first-page":"e000491","DOI":"10.1136\/rmdopen-2017-000491","volume":"3","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Wollenhaupt J, Takiya L et al (2017a) Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. RMD Open 3:e000491. https:\/\/doi.org\/10.1136\/rmdopen-2017-000491","journal-title":"RMD Open"},{"key":"757_CR36","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1002\/art.40319","volume":"69","author":"RM Fleischmann","year":"2017","unstructured":"Fleischmann RM, Wagner F, Kivitz AJ et al (2017b) Safety, tolerability, and pharmacodynamics of ABT-122, a tumor necrosis factor- and interleukin-17-targeted dual variable domain immunoglobulin, in patients with rheumatoid arthritis. Arthritis Rheumatol 69:2283\u20132291. https:\/\/doi.org\/10.1002\/art.40319","journal-title":"Arthritis Rheumatol"},{"key":"757_CR37","doi-asserted-by":"publisher","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","volume":"58","author":"GE Fragoulis","year":"2019","unstructured":"Fragoulis GE, McInnes IB, Siebert S (2019) JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology 58:i43\u2013i54. https:\/\/doi.org\/10.1093\/rheumatology\/key276","journal-title":"Rheumatology"},{"key":"757_CR38","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","volume":"58","author":"M Gadina","year":"2019","unstructured":"Gadina M, Le MT, Schwartz DM et al (2019) Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology 58:i4\u2013i16. https:\/\/doi.org\/10.1093\/rheumatology\/key432","journal-title":"Rheumatology"},{"key":"757_CR39","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","volume":"72","author":"MC Genovese","year":"2013","unstructured":"Genovese MC, Durez P, Richards HB et al (2013) Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 72:863\u2013869. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201601","journal-title":"Ann Rheum Dis"},{"key":"757_CR40","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3899\/jrheum.130637","volume":"41","author":"MC Genovese","year":"2014","unstructured":"Genovese MC, Durez P, Richards HB et al (2014a) One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol 41:414\u2013421. https:\/\/doi.org\/10.3899\/jrheum.130637","journal-title":"J Rheumatol"},{"key":"757_CR41","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1002\/art.38617","volume":"66","author":"MC Genovese","year":"2014","unstructured":"Genovese MC, Greenwald M, Cho C-S et al (2014b) A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors: ixekizumab in biologics-naive and TNF inadequate responder RA patients. Arthritis Rheumatol 66:1693\u20131704. https:\/\/doi.org\/10.1002\/art.38617","journal-title":"Arthritis Rheumatol"},{"key":"757_CR42","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/art.40580","volume":"70","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Weinblatt ME, Aelion JA et al (2018) ABT-122, a bispecific dual variable domain immunoglobulin targeting tumor necrosis factor and interleukin-17A, in patients with rheumatoid arthritis with an inadequate response to methotrexate: a randomized, double-blind study. Arthritis Rheumatol 70:1710\u20131720. https:\/\/doi.org\/10.1002\/art.40580","journal-title":"Arthritis Rheumatol"},{"key":"757_CR43","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg J-E et al (2019) Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA 322:315\u2013325. https:\/\/doi.org\/10.1001\/jama.2019.9055","journal-title":"JAMA"},{"key":"757_CR44","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S2665-9913(20)30032-1","volume":"2","author":"MC Genovese","year":"2020","unstructured":"Genovese MC, Smolen JS, Takeuchi T et al (2020) Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatol 2:e347\u2013e357. https:\/\/doi.org\/10.1016\/S2665-9913(20)30032-1","journal-title":"Lancet Rheumatol"},{"key":"757_CR45","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/annrheumdis-2018-214943","volume":"78","author":"S Glatt","year":"2019","unstructured":"Glatt S, Taylor PC, McInnes IB et al (2019) Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study. Ann Rheum Dis 78:1033\u20131040. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214943","journal-title":"Ann Rheum Dis"},{"key":"757_CR46","doi-asserted-by":"crossref","unstructured":"G\u00f6schl L, M\u00fcller L, Saferding V, et al (2018) P116 Histone deacetylase 1: a novel therapeutic target for patients with rheumatoid arthritis. Ann Rheum Dis 77:A63","DOI":"10.1136\/annrheumdis-2018-EWRR2018.131"},{"key":"757_CR47","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1038\/emboj.2012.125","volume":"31","author":"SN Greer","year":"2012","unstructured":"Greer SN, Metcalf JL, Wang Y, Ohh M (2012) The updated biology of hypoxia-inducible factor. EMBO J 31:2448\u20132460. https:\/\/doi.org\/10.1038\/emboj.2012.125","journal-title":"EMBO J"},{"key":"757_CR48","doi-asserted-by":"publisher","first-page":"e12516","DOI":"10.1371\/journal.pone.0012516","volume":"5","author":"NJ Gullick","year":"2010","unstructured":"Gullick NJ, Evans HG, Church LD et al (2010) Linking power doppler ultrasound to the presence of Th17 cells in the rheumatoid arthritis joint. PLoS One 5:e12516. https:\/\/doi.org\/10.1371\/journal.pone.0012516","journal-title":"PLoS One"},{"key":"757_CR49","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/cei.13167","volume":"194","author":"C Guo","year":"2018","unstructured":"Guo C, Fu R, Wang S et al (2018) NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis. Clin Exp Immunol 194:231\u2013243. https:\/\/doi.org\/10.1111\/cei.13167","journal-title":"Clin Exp Immunol"},{"key":"757_CR50","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1248\/bpb.34.1432","volume":"34","author":"M-K Ha","year":"2011","unstructured":"Ha M-K, Song YH, Jeong S-J et al (2011) Emodin inhibits proinflammatory responses and inactivates histone deacetylase 1 in hypoxic rheumatoid synoviocytes. Biol Pharm Bull 34:1432\u20131437. https:\/\/doi.org\/10.1248\/bpb.34.1432","journal-title":"Biol Pharm Bull"},{"key":"757_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006400.pub2","author":"KB Hagen","year":"2009","unstructured":"Hagen KB, Byfuglien MG, Falzon L et al (2009) Dietary interventions for rheumatoid arthritis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD006400.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"757_CR52","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/jbmr.2828","volume":"31","author":"JL Hamilton","year":"2016","unstructured":"Hamilton JL, Nagao M, Levine BR et al (2016) Targeting VEGF and Its receptors for the treatment of osteoarthritis and associated pain. J Bone Miner Res 31:911\u2013924. https:\/\/doi.org\/10.1002\/jbmr.2828","journal-title":"J Bone Miner Res"},{"key":"757_CR53","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1136\/annrheumdis-2014-eular.4257","volume":"73","author":"W Hardy","year":"2014","unstructured":"Hardy W, Wright F, Hawtree S et al (2014) OP0296 hypoxia-inducible factor 2a regulates macrophage function in rheumatoid arthritis. Ann Rheum Dis 73:1742\u20132174. https:\/\/doi.org\/10.1136\/annrheumdis-2014-eular.4257","journal-title":"Ann Rheum Dis"},{"key":"757_CR54","doi-asserted-by":"publisher","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","volume":"58","author":"M Harigai","year":"2019","unstructured":"Harigai M (2019) Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatol (Oxford) 58:i34\u2013i42. https:\/\/doi.org\/10.1093\/rheumatology\/key287","journal-title":"Rheumatol (Oxford)"},{"key":"757_CR55","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/ni1254","volume":"6","author":"LE Harrington","year":"2005","unstructured":"Harrington LE, Hatton RD, Mangan PR et al (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6:1123\u20131132. https:\/\/doi.org\/10.1038\/ni1254","journal-title":"Nat Immunol"},{"key":"757_CR56","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1002\/art.10520","volume":"46","author":"C Hitchon","year":"2002","unstructured":"Hitchon C, Wong K, Ma G et al (2002) Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum 46:2587\u20132597. https:\/\/doi.org\/10.1002\/art.10520","journal-title":"Arthritis Rheum"},{"key":"757_CR57","doi-asserted-by":"publisher","first-page":"9361","DOI":"10.1128\/mcb.23.24.9361-9374.2003","volume":"23","author":"C-J Hu","year":"2003","unstructured":"Hu C-J, Wang L-Y, Chodosh LA et al (2003) Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 23:9361\u20139374. https:\/\/doi.org\/10.1128\/mcb.23.24.9361-9374.2003","journal-title":"Mol Cell Biol"},{"key":"757_CR58","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1136\/annrheumdis-2012-202444","volume":"73","author":"F Hu","year":"2014","unstructured":"Hu F, Mu R, Zhu J et al (2014) Hypoxia and hypoxia-inducible factor-1\u03b1 provoke toll-like receptor signalling-induced inflammation in rheumatoid arthritis. Ann Rheum Dis 73:928\u2013936. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202444","journal-title":"Ann Rheum Dis"},{"key":"757_CR59","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/eji.201545784","volume":"46","author":"F Hu","year":"2016","unstructured":"Hu F, Liu H, Xu L et al (2016) Hypoxia-inducible factor-1\u03b1 perpetuates synovial fibroblast interactions with T cells and B cells in rheumatoid arthritis. Eur J Immunol 46:742\u2013751. https:\/\/doi.org\/10.1002\/eji.201545784","journal-title":"Eur J Immunol"},{"key":"757_CR60","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3389\/fphar.2016.00184","volume":"7","author":"S Hua","year":"2016","unstructured":"Hua S, Dias TH (2016) Hypoxia-inducible factor (HIF) as a target for novel therapies in rheumatoid arthritis. Front Pharmacol 7:184. https:\/\/doi.org\/10.3389\/fphar.2016.00184","journal-title":"Front Pharmacol"},{"key":"757_CR61","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40259-018-0304-3","volume":"32","author":"F Huang","year":"2018","unstructured":"Huang F, Luo Z-C (2018) Risk of adverse drug events observed with baricitinib 2 mg versus baricitinib 4 mg once daily for the treatment of rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. BioDrugs Clin Immunother Biopharm Gene Ther 32:415\u2013423. https:\/\/doi.org\/10.1007\/s40259-018-0304-3","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"key":"757_CR62","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.3892\/mmr.2018.9280","volume":"18","author":"X Huang","year":"2018","unstructured":"Huang X, Pan Q, Mao Z et al (2018) Kaempferol inhibits interleukin-1\u03b2 stimulated matrix metalloproteinases by suppressing the MAPK-associated ERK and P38 signaling pathways. Mol Med Rep 18:2697\u20132704. https:\/\/doi.org\/10.3892\/mmr.2018.9280","journal-title":"Mol Med Rep"},{"key":"757_CR63","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.4049\/jimmunol.0903566","volume":"184","author":"AJ Hueber","year":"2010","unstructured":"Hueber AJ, Asquith DL, Miller AM et al (2010) Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 184:3336\u20133340. https:\/\/doi.org\/10.4049\/jimmunol.0903566","journal-title":"J Immunol"},{"key":"757_CR64","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1093\/rheumatology\/ket178","volume":"52","author":"J-K Hwang","year":"2013","unstructured":"Hwang J-K, Noh E-M, Moon S-J et al (2013) Emodin suppresses inflammatory responses and joint destruction in collagen-induced arthritic mice. Rheumatol (Oxford) 52:1583\u20131591. https:\/\/doi.org\/10.1093\/rheumatology\/ket178","journal-title":"Rheumatol (Oxford)"},{"key":"757_CR65","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/82_2010_74","volume":"345","author":"HZ Imtiyaz","year":"2010","unstructured":"Imtiyaz HZ, Simon MC (2010) Hypoxia-inducible factors as essential regulators of inflammation. Curr Top Microbiol Immunol 345:105\u2013120. https:\/\/doi.org\/10.1007\/82_2010_74","journal-title":"Curr Top Microbiol Immunol"},{"key":"757_CR66","doi-asserted-by":"publisher","first-page":"5137431","DOI":"10.1155\/2016\/5137431","volume":"2016","author":"MA Islam","year":"2016","unstructured":"Islam MA, Alam F, Solayman M et al (2016) Dietary phytochemicals: natural swords combating inflammation and oxidation-mediated degenerative diseases. Oxid Med Cell Longev 2016:5137431. https:\/\/doi.org\/10.1155\/2016\/5137431","journal-title":"Oxid Med Cell Longev"},{"key":"757_CR67","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1002\/art.11095","volume":"48","author":"LB Ivashkiv","year":"2003","unstructured":"Ivashkiv LB, Hu X (2003) The JAK\/STAT pathway in rheumatoid arthritis: pathogenic or protective? Arthritis Rheum 48:2092\u20132096. https:\/\/doi.org\/10.1002\/art.11095","journal-title":"Arthritis Rheum"},{"key":"757_CR68","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.immuni.2011.02.012","volume":"34","author":"Y Iwakura","year":"2011","unstructured":"Iwakura Y, Ishigame H, Saijo S, Nakae S (2011) Functional specialization of interleukin-17 family members. Immunity 34:149\u2013162. https:\/\/doi.org\/10.1016\/j.immuni.2011.02.012","journal-title":"Immunity"},{"key":"757_CR69","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/art.23152","volume":"58","author":"LAB Joosten","year":"2008","unstructured":"Joosten LAB, Abdollahi-Roodsaz S, Heuvelmans-Jacobs M et al (2008) T cell dependence of chronic destructive murine arthritis induced by repeated local activation of toll-like receptor\u2013driven pathways: crucial role of both interleukin-1\u03b2 and interleukin-17. Arthritis Rheum 58:98\u2013108. https:\/\/doi.org\/10.1002\/art.23152","journal-title":"Arthritis Rheum"},{"key":"757_CR70","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/imr.12287","volume":"265","author":"I Jorgensen","year":"2015","unstructured":"Jorgensen I, Miao EA (2015) Pyroptotic cell death defends against intracellular pathogens. Immunol Rev 265:130\u2013142. https:\/\/doi.org\/10.1111\/imr.12287","journal-title":"Immunol Rev"},{"key":"757_CR71","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000163850","volume":"75","author":"F Kabbinavar","year":"2008","unstructured":"Kabbinavar F, Irl C, Zurlo A, Hurwitz H (2008) Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. Oncology 75:215\u2013223. https:\/\/doi.org\/10.1159\/000163850","journal-title":"Oncology"},{"key":"757_CR72","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/1759720X13485328","volume":"5","author":"H Kellner","year":"2013","unstructured":"Kellner H (2013) Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. Ther Adv Musculoskelet Dis 5:141\u2013152. https:\/\/doi.org\/10.1177\/1759720X13485328","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"757_CR73","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/art.27287","volume":"62","author":"A Kennedy","year":"2010","unstructured":"Kennedy A, Ng CT, Biniecka M et al (2010) Angiogenesis and blood vessel stability in inflammatory arthritis. Arthritis Rheum 62:711\u2013721. https:\/\/doi.org\/10.1002\/art.27287","journal-title":"Arthritis Rheum"},{"key":"757_CR74","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1046\/j.1365-2249.2001.01498.x","volume":"124","author":"S Kerlan-Candon","year":"2001","unstructured":"Kerlan-Candon S, Combe B, Vincent R et al (2001) HLA-DRB1 gene transcripts in rheumatoid arthritis. Clin Exp Immunol 124:142\u2013149","journal-title":"Clin Exp Immunol"},{"key":"757_CR75","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s10067-018-4080-8","volume":"37","author":"HM Khojah","year":"2018","unstructured":"Khojah HM, Ahmed S, Abdel-Rahman MS, Elhakeim EH (2018) Resveratrol as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study. Clin Rheumatol 37:2035\u20132042. https:\/\/doi.org\/10.1007\/s10067-018-4080-8","journal-title":"Clin Rheumatol"},{"key":"757_CR76","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1365-2567.2009.03203.x","volume":"129","author":"SY Kim","year":"2010","unstructured":"Kim SY, Choi YJ, Joung SM et al (2010) Hypoxic stress up-regulates the expression of Toll-like receptor 4 in macrophages via hypoxia-inducible factor. Immunology 129:516\u2013524. https:\/\/doi.org\/10.1111\/j.1365-2567.2009.03203.x","journal-title":"Immunology"},{"key":"757_CR77","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s12272-015-0569-8","volume":"38","author":"GW Kim","year":"2015","unstructured":"Kim GW, Lee NR, Pi RH et al (2015a) IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Arch Pharm Res 38:575\u2013584. https:\/\/doi.org\/10.1007\/s12272-015-0569-8","journal-title":"Arch Pharm Res"},{"key":"757_CR78","doi-asserted-by":"publisher","first-page":"e0124909","DOI":"10.1371\/journal.pone.0124909","volume":"10","author":"H-R Kim","year":"2015","unstructured":"Kim H-R, Kim K-W, Kim B-M et al (2015b) The effect of vascular endothelial growth factor on osteoclastogenesis in rheumatoid arthritis. PLoS One 10:e0124909. https:\/\/doi.org\/10.1371\/journal.pone.0124909","journal-title":"PLoS One"},{"key":"757_CR79","first-page":"630","volume":"35","author":"HW Kim","year":"2017","unstructured":"Kim HW, Kwon Y-J, Park BW et al (2017) Differential expressions of NOD-like receptors and their associations with inflammatory responses in rheumatoid arthritis. Clin Exp Rheumatol 35:630\u2013637","journal-title":"Clin Exp Rheumatol"},{"key":"757_CR80","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.intimp.2013.01.003","volume":"15","author":"B Kloesch","year":"2013","unstructured":"Kloesch B, Becker T, Dietersdorfer E et al (2013) Anti-inflammatory and apoptotic effects of the polyphenol curcumin on human fibroblast-like synoviocytes. Int Immunopharmacol 15:400\u2013405. https:\/\/doi.org\/10.1016\/j.intimp.2013.01.003","journal-title":"Int Immunopharmacol"},{"key":"757_CR81","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.tips.2015.02.001","volume":"36","author":"MI Koenders","year":"2015","unstructured":"Koenders MI, van den Berg WB (2015) Novel therapeutic targets in rheumatoid arthritis. Trends Pharmacol Sci 36:189\u2013195. https:\/\/doi.org\/10.1016\/j.tips.2015.02.001","journal-title":"Trends Pharmacol Sci"},{"key":"757_CR82","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrrheum.2011.205","volume":"8","author":"S Konisti","year":"2012","unstructured":"Konisti S, Kiriakidis S, Paleolog EM (2012) Hypoxia\u2013a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nat Rev Rheumatol 8:153\u2013162. https:\/\/doi.org\/10.1038\/nrrheum.2011.205","journal-title":"Nat Rev Rheumatol"},{"key":"757_CR83","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","volume":"27","author":"T Korn","year":"2009","unstructured":"Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 cells. Annu Rev Immunol 27:485\u2013517. https:\/\/doi.org\/10.1146\/annurev.immunol.021908.132710","journal-title":"Annu Rev Immunol"},{"key":"757_CR84","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1136\/annrheumdis-2013-203756","volume":"73","author":"S Kubo","year":"2014","unstructured":"Kubo S, Yamaoka K, Kondo M et al (2014) The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis 73:2192\u20132198. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203756","journal-title":"Ann Rheum Dis"},{"key":"757_CR85","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4137\/CMAMD.S5558","volume":"6","author":"P Kumar","year":"2013","unstructured":"Kumar P, Banik S (2013) Pharmacotherapy options in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 6:35\u201343. https:\/\/doi.org\/10.4137\/CMAMD.S5558","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"},{"key":"757_CR86","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-11-0682","volume":"17","author":"S Kummar","year":"2011","unstructured":"Kummar S, Raffeld M, Juwara L et al (2011) Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1\u03b1 in advanced solid tumors. Clin Cancer Res 17:5123\u20135131. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0682","journal-title":"Clin Cancer Res"},{"key":"757_CR87","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00296-016-3480-9","volume":"36","author":"S Kunwar","year":"2016","unstructured":"Kunwar S, Dahal K, Sharma S (2016) Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatol Int 36:1065\u20131075. https:\/\/doi.org\/10.1007\/s00296-016-3480-9","journal-title":"Rheumatol Int"},{"key":"757_CR88","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cyto.2016.09.019","volume":"88","author":"F Lavocat","year":"2016","unstructured":"Lavocat F, Maggi L, Annunziato F, Miossec P (2016) T-cell clones from Th1, Th17 or Th1\/17 lineages and their signature cytokines have different capacity to activate endothelial cells or synoviocytes. Cytokine 88:241\u2013250. https:\/\/doi.org\/10.1016\/j.cyto.2016.09.019","journal-title":"Cytokine"},{"key":"757_CR89","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/art.24245","volume":"60","author":"H-S Lee","year":"2009","unstructured":"Lee H-S, Korman BD, Le JM et al (2009) Genetic risk factors for rheumatoid arthritis differ in Caucasian and Korean populations. Arthritis Rheum 60:364\u2013371. https:\/\/doi.org\/10.1002\/art.24245","journal-title":"Arthritis Rheum"},{"key":"757_CR90","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377\u20132386. https:\/\/doi.org\/10.1056\/NEJMoa1310476","journal-title":"N Engl J Med"},{"key":"757_CR91","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10067-012-2148-4","volume":"32","author":"J Li","year":"2013","unstructured":"Li J, Gang D, Yu X et al (2013a) Genistein: the potential for efficacy in rheumatoid arthritis. Clin Rheumatol 32:535\u2013540. https:\/\/doi.org\/10.1007\/s10067-012-2148-4","journal-title":"Clin Rheumatol"},{"key":"757_CR92","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9899.1000174","author":"S Li","year":"2013","unstructured":"Li S, Yu Y, Yue Y et al (2013b) Microbial infection and rheumatoid arthritis. J Clin Cell Immunol. https:\/\/doi.org\/10.4172\/2155-9899.1000174","journal-title":"J Clin Cell Immunol"},{"key":"757_CR93","doi-asserted-by":"publisher","first-page":"6020","DOI":"10.3390\/nu6126020","volume":"6","author":"A-N Li","year":"2014","unstructured":"Li A-N, Li S, Zhang Y-J et al (2014) Resources and biological activities of natural polyphenols. Nutrients 6:6020\u20136047. https:\/\/doi.org\/10.3390\/nu6126020","journal-title":"Nutrients"},{"key":"757_CR94","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.lfs.2015.06.019","volume":"136","author":"G Li","year":"2015","unstructured":"Li G, Qin Y, Du P (2015) Andrographolide inhibits the migration, invasion and matrix metalloproteinase expression of rheumatoid arthritis fibroblast-like synoviocytes via inhibition of HIF-1\u03b1 signaling. Life Sci 136:67\u201372. https:\/\/doi.org\/10.1016\/j.lfs.2015.06.019","journal-title":"Life Sci"},{"key":"757_CR95","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.1038\/s41598-017-05014-8","volume":"7","author":"S Li","year":"2017","unstructured":"Li S, Yin H, Zhang K et al (2017) Effector T helper cell populations are elevated in the bone marrow of rheumatoid arthritis patients and correlate with disease severity. Sci Rep 7:4776. https:\/\/doi.org\/10.1038\/s41598-017-05014-8","journal-title":"Sci Rep"},{"key":"757_CR96","doi-asserted-by":"publisher","first-page":"5922","DOI":"10.4049\/jimmunol.164.11.5922","volume":"164","author":"J Lu","year":"2000","unstructured":"Lu J, Kasama T, Kobayashi K et al (2000) Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. J Immunol 164:5922\u20135927. https:\/\/doi.org\/10.4049\/jimmunol.164.11.5922","journal-title":"J Immunol"},{"key":"757_CR97","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.4049\/jimmunol.167.2.1004","volume":"167","author":"E Lubberts","year":"2001","unstructured":"Lubberts E, Joosten LA, Oppers B et al (2001) IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 167:1004\u20131013","journal-title":"J Immunol"},{"key":"757_CR98","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3892\/br.2012.42","volume":"1","author":"X Ma","year":"2013","unstructured":"Ma X, Xu S (2013) TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep 1:177\u2013184. https:\/\/doi.org\/10.3892\/br.2012.42","journal-title":"Biomed Rep"},{"key":"757_CR99","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4172\/2155-9899.1000160","volume":"4","author":"CJ Malemud","year":"2013","unstructured":"Malemud CJ (2013) Intracellular signaling pathways in rheumatoid arthritis. J Clin Cell Immunol 4:160. https:\/\/doi.org\/10.4172\/2155-9899.1000160","journal-title":"J Clin Cell Immunol"},{"key":"757_CR100","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nri.2016.124","volume":"17","author":"V Malmstr\u00f6m","year":"2017","unstructured":"Malmstr\u00f6m V, Catrina AI, Klareskog L (2017) The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol 17:60\u201375. https:\/\/doi.org\/10.1038\/nri.2016.124","journal-title":"Nat Rev Immunol"},{"key":"757_CR101","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrd.2018.97","volume":"17","author":"MSJ Mangan","year":"2018","unstructured":"Mangan MSJ, Olhava EJ, Roush WR et al (2018) Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov 17:588","journal-title":"Nat Rev Drug Discov"},{"key":"757_CR102","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.autrev.2011.04.020","volume":"10","author":"A Marrelli","year":"2011","unstructured":"Marrelli A, Cipriani P, Liakouli V et al (2011) Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? Autoimmun Rev 10:595\u2013598. https:\/\/doi.org\/10.1016\/j.autrev.2011.04.020","journal-title":"Autoimmun Rev"},{"key":"757_CR103","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.joca.2018.02.901","volume":"26","author":"MJ McAllister","year":"2018","unstructured":"McAllister MJ, Chemaly M, Eakin AJ et al (2018) NLRP3 as a potentially novel biomarker for the management of osteoarthritis. Osteoarthritis Cartilage 26:612\u2013619. https:\/\/doi.org\/10.1016\/j.joca.2018.02.901","journal-title":"Osteoarthritis Cartilage"},{"key":"757_CR104","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB et al (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382:780\u2013789. https:\/\/doi.org\/10.1016\/S0140-6736(13)60594-2","journal-title":"Lancet"},{"key":"757_CR105","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10067-011-1737-y","volume":"30","author":"SA Metawi","year":"2011","unstructured":"Metawi SA, Abbas D, Kamal MM, Ibrahim MK (2011) Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol 30:1201\u20131207. https:\/\/doi.org\/10.1007\/s10067-011-1737-y","journal-title":"Clin Rheumatol"},{"key":"757_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00729","author":"AM Mileo","year":"2019","unstructured":"Mileo AM, Nistic\u00f2 P, Miccadei S (2019) Polyphenols: immunomodulatory and therapeutic implication in colorectal cancer. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.00729","journal-title":"Front Immunol"},{"key":"757_CR107","doi-asserted-by":"publisher","first-page":"R113","DOI":"10.1186\/ar2772","volume":"11","author":"EM Moran","year":"2009","unstructured":"Moran EM, Mullan R, McCormick J et al (2009) Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-\u03b1, Oncostatin M and response to biologic therapies. Arthritis Res Ther 11:R113. https:\/\/doi.org\/10.1186\/ar2772","journal-title":"Arthritis Res Ther"},{"key":"757_CR108","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJM199707173370301","volume":"337","author":"LW Moreland","year":"1997","unstructured":"Moreland LW, Baumgartner SW, Schiff MH et al (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141\u2013147. https:\/\/doi.org\/10.1056\/NEJM199707173370301","journal-title":"N Engl J Med"},{"key":"757_CR109","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1002\/art.34498","volume":"64","author":"LW Moreland","year":"2012","unstructured":"Moreland LW, O\u2019Dell JR, Paulus HE et al (2012) A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum 64:2824\u20132835. https:\/\/doi.org\/10.1002\/art.34498","journal-title":"Arthritis Rheum"},{"key":"757_CR110","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2020.1770948","author":"A Morinobu","year":"2020","unstructured":"Morinobu A (2020) JAK inhibitors for the treatment of rheumatoid arthritis. Immunol Med. https:\/\/doi.org\/10.1080\/25785826.2020.1770948","journal-title":"Immunol Med"},{"key":"757_CR111","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.3390\/jcm8101548","volume":"8","author":"H Mueller","year":"2019","unstructured":"Mueller H, Popp, et al (2019) Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the St Gallen and Aarau cohorts. J Clin Med 8:1548. https:\/\/doi.org\/10.3390\/jcm8101548","journal-title":"J Clin Med"},{"key":"757_CR112","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0014-5793(00)01520-9","volume":"473","author":"M Nakagawa","year":"2000","unstructured":"Nakagawa M, Kaneda T, Arakawa T et al (2000) Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 473:161\u2013164","journal-title":"FEBS Lett"},{"key":"757_CR113","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1136\/annrheumdis-2016-209149","volume":"75","author":"N Ndongo-Thiam","year":"2016","unstructured":"Ndongo-Thiam N, Clement A, Pin J-J et al (2016) Negative association between autoantibodies against IL-17, IL-17\/anti-IL-17 antibody immune complexes and destruction in rheumatoid arthritis. Ann Rheum Dis 75:1420\u20131422. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209149","journal-title":"Ann Rheum Dis"},{"key":"757_CR114","doi-asserted-by":"publisher","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","volume":"72","author":"JJ O\u2019Shea","year":"2013","unstructured":"O\u2019Shea JJ, Kontzias A, Yamaoka K et al (2013) Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 72:ii111\u2013ii115. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202576","journal-title":"Ann Rheum Dis"},{"key":"757_CR115","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Olivera PA, Lasa JS, Bonovas S et al (2020) Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology 158:1554\u20131573.e12. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.001","journal-title":"Gastroenterology"},{"key":"757_CR116","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/jsfa.8664","volume":"98","author":"F Oliviero","year":"2018","unstructured":"Oliviero F, Scanu A, Zamudio-Cuevas Y et al (2018) Anti-inflammatory effects of polyphenols in arthritis. J Sci Food Agric 98:1653\u20131659. https:\/\/doi.org\/10.1002\/jsfa.8664","journal-title":"J Sci Food Agric"},{"key":"757_CR117","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrrheum.2017.115","volume":"13","author":"C Orr","year":"2017","unstructured":"Orr C, Vieira-Sousa E, Boyle DL et al (2017) Synovial tissue research: a state-of-the-art review. Nat Rev Rheumatol 13:463\u2013475. https:\/\/doi.org\/10.1038\/nrrheum.2017.115","journal-title":"Nat Rev Rheumatol"},{"key":"757_CR118","doi-asserted-by":"publisher","first-page":"148","DOI":"10.12788\/j.sder.2018.051","volume":"37","author":"SY Paek","year":"2018","unstructured":"Paek SY, Frieder J, Kivelevitch D, Menter MA (2018) IL-17 inhibitors for psoriasis. Semin Cutan Med Surg 37:148\u2013157. https:\/\/doi.org\/10.12788\/j.sder.2018.051","journal-title":"Semin Cutan Med Surg"},{"key":"757_CR119","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3899\/jrheum.141271","volume":"42","author":"K Pavelka","year":"2015","unstructured":"Pavelka K, Chon Y, Newmark R et al (2015) A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. J Rheumatol 42:912\u2013919. https:\/\/doi.org\/10.3899\/jrheum.141271","journal-title":"J Rheumatol"},{"key":"757_CR120","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00280-015-2920-7","volume":"77","author":"RM Phillips","year":"2016","unstructured":"Phillips RM (2016) Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs. Cancer Chemother Pharmacol 77:441\u2013457. https:\/\/doi.org\/10.1007\/s00280-015-2920-7","journal-title":"Cancer Chemother Pharmacol"},{"key":"757_CR121","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5539\/gjhs.v8n7p18","volume":"8","author":"E Rajaei","year":"2015","unstructured":"Rajaei E, Mowla K, Ghorbani A et al (2015) The effect of omega-3 fatty acids in patients with active rheumatoid arthritis receiving dmards therapy: double-blind randomized controlled trial. Glob J Health Sci 8:18\u201325. https:\/\/doi.org\/10.5539\/gjhs.v8n7p18","journal-title":"Glob J Health Sci"},{"key":"757_CR122","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10753-010-9278-0","volume":"34","author":"G Ramadan","year":"2011","unstructured":"Ramadan G, Al-Kahtani MA, El-Sayed WM (2011) Anti-inflammatory and anti-oxidant properties of Curcuma longa (turmeric) versus Zingiber officinale (ginger) rhizomes in rat adjuvant-induced arthritis. Inflammation 34:291\u2013301. https:\/\/doi.org\/10.1007\/s10753-010-9278-0","journal-title":"Inflammation"},{"key":"757_CR123","first-page":"4316","volume":"62","author":"A Rapisarda","year":"2002","unstructured":"Rapisarda A, Uranchimeg B, Scudiero DA et al (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62:4316\u20134324","journal-title":"Cancer Res"},{"key":"757_CR124","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3164\/jcbn.2007002","volume":"41","author":"B Rathore","year":"2007","unstructured":"Rathore B, Ali Mahdi A, Nath Paul B et al (2007) Indian herbal medicines: possible potent therapeutic agents for rheumatoid arthritis. J Clin Biochem Nutr 41:12\u201317. https:\/\/doi.org\/10.3164\/jcbn.2007002","journal-title":"J Clin Biochem Nutr"},{"key":"757_CR125","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/509269a","volume":"509","author":"S Reardon","year":"2014","unstructured":"Reardon S (2014) Microbiome therapy gains market traction. Nature 509:269\u2013270. https:\/\/doi.org\/10.1038\/509269a","journal-title":"Nature"},{"key":"757_CR126","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/bjd.12643","volume":"170","author":"K Reich","year":"2014","unstructured":"Reich K, Puig L, Paul C et al (2014) One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis. Br J Dermatol 170:435\u2013444. https:\/\/doi.org\/10.1111\/bjd.12643","journal-title":"Br J Dermatol"},{"key":"757_CR127","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJMoa073003","volume":"357","author":"EF Remmers","year":"2007","unstructured":"Remmers EF, Plenge RM, Lee AT et al (2007) STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 357:977\u2013986. https:\/\/doi.org\/10.1056\/NEJMoa073003","journal-title":"N Engl J Med"},{"key":"757_CR128","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/ana.25608","volume":"86","author":"LB Reoma","year":"2019","unstructured":"Reoma LB, Trindade CJ, Monaco MC et al (2019) Fatal encephalopathy with wild-type JC virus and ruxolitinib therapy. Ann Neurol 86:878\u2013884. https:\/\/doi.org\/10.1002\/ana.25608","journal-title":"Ann Neurol"},{"key":"757_CR129","doi-asserted-by":"publisher","first-page":"9259646","DOI":"10.1155\/2016\/9259646","volume":"2016","author":"P Rider","year":"2016","unstructured":"Rider P, Carmi Y, Cohen I (2016) Biologics for targeting inflammatory cytokines, clinical uses, and limitations. Int J Cell Biol 2016:9259646. https:\/\/doi.org\/10.1155\/2016\/9259646","journal-title":"Int J Cell Biol"},{"key":"757_CR130","doi-asserted-by":"publisher","DOI":"10.2174\/0929867325666180209145243","author":"F Rivellese","year":"2018","unstructured":"Rivellese F, Lobasso A, Barbieri L et al (2018) Novel therapeutic approaches in rheumatoid arthritis: role of Janus kinases inhibitors. Curr Med Chem. https:\/\/doi.org\/10.2174\/0929867325666180209145243","journal-title":"Curr Med Chem"},{"key":"757_CR131","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaut.2016.10.005","volume":"77","author":"M Rizzi","year":"2017","unstructured":"Rizzi M, Lorenzetti R, Fischer K et al (2017) Impact of tofacitinib treatment on human B-cells in vitro and in vivo. J Autoimmun 77:55\u201366. https:\/\/doi.org\/10.1016\/j.jaut.2016.10.005","journal-title":"J Autoimmun"},{"key":"757_CR132","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00364","author":"M Robert","year":"2019","unstructured":"Robert M, Miossec P (2019) IL-17 in rheumatoid arthritis and precision medicine: from synovitis expression to circulating bioactive levels. Front Med. https:\/\/doi.org\/10.3389\/fmed.2018.00364","journal-title":"Front Med"},{"key":"757_CR133","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.jnutbio.2014.07.006","volume":"25","author":"M\u00c1 Rosillo","year":"2014","unstructured":"Rosillo M\u00c1, Alcaraz MJ, S\u00e1nchez-Hidalgo M et al (2014) Anti-inflammatory and joint protective effects of extra-virgin olive-oil polyphenol extract in experimental arthritis. J Nutr Biochem 25:1275\u20131281. https:\/\/doi.org\/10.1016\/j.jnutbio.2014.07.006","journal-title":"J Nutr Biochem"},{"key":"757_CR134","doi-asserted-by":"publisher","first-page":"A81.1","DOI":"10.1136\/annrheumdis-2015-207259.186","volume":"74","author":"E Ross","year":"2015","unstructured":"Ross E, Smallie T, Naylor A et al (2015) A8.1 Tristetraprolin is a novel therapeutic target for rheumatoid arthritis. Ann Rheum Dis 74:A81.1\u2013A81. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207259.186","journal-title":"Ann Rheum Dis"},{"key":"757_CR135","doi-asserted-by":"publisher","first-page":"010409","DOI":"10.7189\/jogh.05.010409","volume":"5","author":"I Rudan","year":"2015","unstructured":"Rudan I, Sidhu S, Papana A et al (2015) Prevalence of rheumatoid arthritis in low- and middle-income countries: a systematic review and analysis. J Glob Health 5:010409. https:\/\/doi.org\/10.7189\/jogh.05.010409","journal-title":"J Glob Health"},{"key":"757_CR136","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/cei.12667","volume":"182","author":"P Ruscitti","year":"2015","unstructured":"Ruscitti P, Cipriani P, Di Benedetto P et al (2015) Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1\u03b2 via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. Clin Exp Immunol 182:35\u201344. https:\/\/doi.org\/10.1111\/cei.12667","journal-title":"Clin Exp Immunol"},{"key":"757_CR137","doi-asserted-by":"publisher","first-page":"e1001881","DOI":"10.1371\/journal.pbio.1001881","volume":"12","author":"J-H Ryu","year":"2014","unstructured":"Ryu J-H, Chae C-S, Kwak J-S et al (2014) Hypoxia-inducible factor-2\u03b1 is an essential catabolic regulator of inflammatory rheumatoid arthritis. PLoS Biol 12:e1001881. https:\/\/doi.org\/10.1371\/journal.pbio.1001881","journal-title":"PLoS Biol"},{"key":"757_CR138","doi-asserted-by":"publisher","DOI":"10.2174\/1871530317666171114114321","author":"C Santangelo","year":"2017","unstructured":"Santangelo C, Vari R, Scazzocchio B et al (2017) Anti-inflammatory activity of extra virgin olive oil polyphenols: which role in the prevention and treatment of immune-mediated inflammatory diseases? Endocr Metab Immune Disord Drug Targets. https:\/\/doi.org\/10.2174\/1871530317666171114114321","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"757_CR139","doi-asserted-by":"publisher","DOI":"10.4172\/2161-1459.1000231","author":"A Sarkar","year":"2017","unstructured":"Sarkar A, Tripathi VD, Sahu RK (2017) Anti-inflammatory and anti-arthritis activity of flavonoids fractions isolated from Centipeda minima leaves extracts in rats. Clin Exp Pharmacol. https:\/\/doi.org\/10.4172\/2161-1459.1000231","journal-title":"Clin Exp Pharmacol"},{"key":"757_CR140","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/rheumatology\/kew329","volume":"56","author":"H Schulze-Koops","year":"2017","unstructured":"Schulze-Koops H, Strand V, Nduaka C et al (2017) Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Rheumatology 56:46\u201357. https:\/\/doi.org\/10.1093\/rheumatology\/kew329","journal-title":"Rheumatology"},{"key":"757_CR141","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A et al (2017) JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 16:843","journal-title":"Nat Rev Drug Discov"},{"key":"757_CR142","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrd.2017.267","volume":"17","author":"DM Schwartz","year":"2018","unstructured":"Schwartz DM, Kanno Y, Villarino A et al (2018) Erratum: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 17:78\u201378. https:\/\/doi.org\/10.1038\/nrd.2017.267","journal-title":"Nat Rev Drug Discov"},{"key":"757_CR143","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.bbrc.2009.01.086","volume":"387","author":"J Shankar","year":"2009","unstructured":"Shankar J, Thippegowda PB, Kanum SA (2009) Inhibition of HIF-1alpha activity by BP-1 ameliorates adjuvant induced arthritis in rats. Biochem Biophys Res Commun 387:223\u2013228. https:\/\/doi.org\/10.1016\/j.bbrc.2009.01.086","journal-title":"Biochem Biophys Res Commun"},{"key":"757_CR144","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.autrev.2018.01.020","volume":"17","author":"H-H Shen","year":"2018","unstructured":"Shen H-H, Yang Y-X, Meng X et al (2018) NLRP3: a promising therapeutic target for autoimmune diseases. Autoimmun Rev 17:694\u2013702. https:\/\/doi.org\/10.1016\/j.autrev.2018.01.020","journal-title":"Autoimmun Rev"},{"key":"757_CR145","doi-asserted-by":"publisher","first-page":"3109135","DOI":"10.1155\/2016\/3109135","volume":"2016","author":"I Silo\u015fi","year":"2016","unstructured":"Silo\u015fi I, Boldeanu MV, Cojocaru M et al (2016) The relationship of cytokines IL-13 and IL-17 with autoantibodies profile in early rheumatoid arthritis. J Immunol Res 2016:3109135. https:\/\/doi.org\/10.1155\/2016\/3109135","journal-title":"J Immunol Res"},{"key":"757_CR146","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/art.39447","volume":"68","author":"AK Singh","year":"2016","unstructured":"Singh AK, Umar S, Riegsecker S et al (2016) Regulation of transforming growth factor \u03b2-activated kinase activation by epigallocatechin-3-gallate in rheumatoid arthritis synovial fibroblasts: suppression of K(63)-linked autoubiquitination of tumor necrosis factor receptor-associated factor 6. Arthritis Rheumatol 68:347\u2013358. https:\/\/doi.org\/10.1002\/art.39447","journal-title":"Arthritis Rheumatol"},{"key":"757_CR147","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3899\/jrheum.171361","volume":"46","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Genovese MC, Takeuchi T et al (2019) Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol 46:7\u201318. https:\/\/doi.org\/10.3899\/jrheum.171361","journal-title":"J Rheumatol"},{"key":"757_CR148","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/rheumatology\/keg183","volume":"42","author":"KL Soeken","year":"2003","unstructured":"Soeken KL, Miller SA, Ernst E (2003) Herbal medicines for the treatment of rheumatoid arthritis: a systematic review. Rheumatol (Oxford) 42:652\u2013659. https:\/\/doi.org\/10.1093\/rheumatology\/keg183","journal-title":"Rheumatol (Oxford)"},{"key":"757_CR149","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/ar2500","volume":"10","author":"S Strietholt","year":"2008","unstructured":"Strietholt S, Maurer B, Peters MA et al (2008) Epigenetic modifications in rheumatoid arthritis. Arthritis Res Ther 10:219. https:\/\/doi.org\/10.1186\/ar2500","journal-title":"Arthritis Res Ther"},{"key":"757_CR150","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1111\/1756-185X.13202","volume":"20","author":"L-C Su","year":"2017","unstructured":"Su L-C, Huang A-F, Jia H et al (2017) Role of microRNA-155 in rheumatoid arthritis. Int J Rheum Dis 20:1631\u20131637. https:\/\/doi.org\/10.1111\/1756-185X.13202","journal-title":"Int J Rheum Dis"},{"key":"757_CR151","doi-asserted-by":"publisher","first-page":"e20192048","DOI":"10.1084\/jem.20192048","volume":"217","author":"LS Taams","year":"2020","unstructured":"Taams LS (2020) Interleukin-17 in rheumatoid arthritis: trials and tribulations. J Exp Med 217:e20192048. https:\/\/doi.org\/10.1084\/jem.20192048","journal-title":"J Exp Med"},{"key":"757_CR152","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/art.40680","volume":"70","author":"Y Tanaka","year":"2018","unstructured":"Tanaka Y, McInnes IB, Taylor PC et al (2018) Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis. Arthritis Rheumatol 70:1923\u20131932. https:\/\/doi.org\/10.1002\/art.40680","journal-title":"Arthritis Rheumatol"},{"key":"757_CR153","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/01.bor.0000155361.83990.5b","volume":"17","author":"PC Taylor","year":"2005","unstructured":"Taylor PC, Sivakumar B (2005) Hypoxia and angiogenesis in rheumatoid arthritis. Curr Opin Rheumatol 17:293\u2013298","journal-title":"Curr Opin Rheumatol"},{"key":"757_CR154","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/art.40841","volume":"71","author":"PC Taylor","year":"2019","unstructured":"Taylor PC, Weinblatt ME, Burmester GR et al (2019) Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol 71:1042\u20131055. https:\/\/doi.org\/10.1002\/art.40841","journal-title":"Arthritis Rheumatol"},{"key":"757_CR155","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s00296-012-2657-0","volume":"33","author":"J Tian","year":"2013","unstructured":"Tian J, Chen J, Gao J et al (2013) Resveratrol inhibits TNF-\u03b1-induced IL-1\u03b2, MMP-3 production in human rheumatoid arthritis fibroblast-like synoviocytes via modulation of PI3kinase\/Akt pathway. Rheumatol Int 33:1829\u20131835. https:\/\/doi.org\/10.1007\/s00296-012-2657-0","journal-title":"Rheumatol Int"},{"key":"757_CR156","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaut.2009.12.009","volume":"35","author":"GJ Tob\u00f3n","year":"2010","unstructured":"Tob\u00f3n GJ, Youinou P, Saraux A (2010) The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. J Autoimmun 35:10\u201314. https:\/\/doi.org\/10.1016\/j.jaut.2009.12.009","journal-title":"J Autoimmun"},{"key":"757_CR157","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1741-7015-7-12","volume":"7","author":"RF van Vollenhoven","year":"2009","unstructured":"van Vollenhoven RF (2009) Sex differences in rheumatoid arthritis: more than meets the eye. BMC Med 7:12. https:\/\/doi.org\/10.1186\/1741-7015-7-12","journal-title":"BMC Med"},{"key":"757_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/annrheumdis-2016-eular.2134","volume":"75","author":"R van Vollenhoven","year":"2016","unstructured":"van Vollenhoven R, Choy E, Lee EB et al (2016) THU0199 tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: changes in lymphocytes and lymphocyte subset counts and reversibility after up to 8 years of tofacitinib treatment. Ann Rheum Dis 75:1\u2013258. https:\/\/doi.org\/10.1136\/annrheumdis-2016-eular.2134","journal-title":"Ann Rheum Dis"},{"key":"757_CR159","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/art.40780","volume":"71","author":"R van Vollenhoven","year":"2019","unstructured":"van Vollenhoven R, Lee EB, Strengholt S et al (2019) Evaluation of the short-, mid-, and long-term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis. Arthritis Rheumatol 71:685\u2013695. https:\/\/doi.org\/10.1002\/art.40780","journal-title":"Arthritis Rheumatol"},{"key":"757_CR160","first-page":"1650","volume":"32","author":"JG Walker","year":"2005","unstructured":"Walker JG, Smith MD (2005) The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol 32:1650\u20131653","journal-title":"J Rheumatol"},{"key":"757_CR161","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.maturitas.2008.04.003","volume":"59","author":"J Wang","year":"2008","unstructured":"Wang J, Zhang Q, Jin S et al (2008) Genistein modulate immune responses in collagen-induced rheumatoid arthritis model. Maturitas 59:405\u2013412. https:\/\/doi.org\/10.1016\/j.maturitas.2008.04.003","journal-title":"Maturitas"},{"key":"757_CR162","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1096\/fj.04-1640fje","volume":"18","author":"C Warnecke","year":"2004","unstructured":"Warnecke C, Zaborowska Z, Kurreck J et al (2004) Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J 18:1462\u20131464. https:\/\/doi.org\/10.1096\/fj.04-1640fje","journal-title":"FASEB J"},{"key":"757_CR163","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.2147\/DDDT.S91374","volume":"10","author":"M Wei","year":"2016","unstructured":"Wei M, Duan D (2016) Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials. Drug Des Devel Ther 10:2771\u20132777. https:\/\/doi.org\/10.2147\/DDDT.S91374","journal-title":"Drug Des Devel Ther"},{"key":"757_CR164","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1471-2474-11-61","volume":"11","author":"J Westra","year":"2010","unstructured":"Westra J, Brouwer E, van Roosmalen IAM et al (2010) Expression and regulation of HIF-1alpha in macrophages under inflammatory conditions; significant reduction of VEGF by CaMKII inhibitor. BMC Musculoskelet Disord 11:61. https:\/\/doi.org\/10.1186\/1471-2474-11-61","journal-title":"BMC Musculoskelet Disord"},{"key":"757_CR165","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00296-009-1111-4","volume":"30","author":"A Wiens","year":"2010","unstructured":"Wiens A, Correr CJ, Venson R et al (2010) A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis. Rheumatol Int 30:1063\u20131070. https:\/\/doi.org\/10.1007\/s00296-009-1111-4","journal-title":"Rheumatol Int"},{"key":"757_CR166","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pharmthera.2016.04.009","volume":"164","author":"C Wigerup","year":"2016","unstructured":"Wigerup C, P\u00e5hlman S, Bexell D (2016) Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther 164:152\u2013169. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.04.009","journal-title":"Pharmacol Ther"},{"key":"757_CR167","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL (2017) The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 13:234\u2013243. https:\/\/doi.org\/10.1038\/nrrheum.2017.23","journal-title":"Nat Rev Rheumatol"},{"key":"757_CR168","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Park S-H, Gul A et al (2016) Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis 75:1133\u20131138. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207319","journal-title":"Ann Rheum Dis"},{"key":"757_CR169","first-page":"524","volume":"19","author":"AM Wolfe","year":"1968","unstructured":"Wolfe AM, Kellgren JH, Masi AT (1968) The epidemiology of rheumatoid arthritis: a review. II. Incidence and diagnostic criteria. Bull Rheum Dis 19:524\u2013529","journal-title":"Bull Rheum Dis"},{"key":"757_CR170","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3899\/jrheum.130683","volume":"41","author":"J Wollenhaupt","year":"2014","unstructured":"Wollenhaupt J, Silverfield J, Lee EB et al (2014) Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 41:837\u2013852. https:\/\/doi.org\/10.3899\/jrheum.130683","journal-title":"J Rheumatol"},{"key":"757_CR171","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt J, Lee E-B, Curtis JR et al (2019) Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther 21:89. https:\/\/doi.org\/10.1186\/s13075-019-1866-2","journal-title":"Arthritis Res Ther"},{"key":"757_CR172","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","volume":"78","author":"W Xie","year":"2019","unstructured":"Xie W, Huang Y, Xiao S et al (2019a) Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 78:1048\u20131054. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214846","journal-title":"Ann Rheum Dis"},{"key":"757_CR173","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19895492","author":"W Xie","year":"2019","unstructured":"Xie W, Xiao S, Huang Y et al (2019b) Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Musculoskelet Dis. https:\/\/doi.org\/10.1177\/1759720X19895492","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"757_CR174","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/ard.2011.149831","volume":"71","author":"G Xuzhu","year":"2012","unstructured":"Xuzhu G, Komai-Koma M, Leung BP et al (2012) Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann Rheum Dis 71:129\u2013135. https:\/\/doi.org\/10.1136\/ard.2011.149831","journal-title":"Ann Rheum Dis"},{"key":"757_CR175","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.4049\/jimmunol.155.12.5483","volume":"155","author":"Z Yao","year":"1995","unstructured":"Yao Z, Painter SL, Fanslow WC et al (1995) Human IL-17: a novel cytokine derived from T cells. J Immunol 155:5483\u20135486","journal-title":"J Immunol"},{"key":"757_CR176","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3892\/ijmm.2013.1468","volume":"32","author":"H-Y Yoon","year":"2013","unstructured":"Yoon H-Y, Lee E-G, Lee H et al (2013) Kaempferol inhibits IL-1\u03b2-induced proliferation of rheumatoid arthritis synovial fibroblasts and the production of COX-2, PGE2 and MMPs. Int J Mol Med 32:971\u2013977. https:\/\/doi.org\/10.3892\/ijmm.2013.1468","journal-title":"Int J Mol Med"},{"key":"757_CR177","doi-asserted-by":"publisher","first-page":"9656270","DOI":"10.1155\/2016\/9656270","volume":"2016","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Zheng Y, Li H (2016) NLRP3 inflammasome plays an important role in the pathogenesis of collagen-induced arthritis. Mediators Inflamm 2016:9656270. https:\/\/doi.org\/10.1155\/2016\/9656270","journal-title":"Mediators Inflamm"},{"key":"757_CR178","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.2147\/DDDT.S90147","volume":"9","author":"Z Zheng","year":"2015","unstructured":"Zheng Z, Sun Y, Liu Z et al (2015) The effect of curcumin and its nanoformulation on adjuvant-induced arthritis in rats. Drug Des Devel Ther 9:4931\u20134942. https:\/\/doi.org\/10.2147\/DDDT.S90147","journal-title":"Drug Des Devel Ther"},{"key":"757_CR179","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.molimm.2019.05.010","volume":"112","author":"M Zhu","year":"2019","unstructured":"Zhu M, Yuan K, Lu Q et al (2019) Emodin ameliorates rheumatoid arthritis by promoting neutrophil apoptosis and inhibiting neutrophil extracellular trap formation. Mol Immunol 112:188\u2013197. https:\/\/doi.org\/10.1016\/j.molimm.2019.05.010","journal-title":"Mol Immunol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-020-00757-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-020-00757-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-020-00757-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T15:19:27Z","timestamp":1696691967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-020-00757-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":179,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["757"],"URL":"https:\/\/doi.org\/10.1007\/s10787-020-00757-9","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,18]]},"assertion":[{"value":"18 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}